What is Wedbush’s Estimate for ZNTL FY2025 Earnings?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Equities research analysts at Wedbush upped their FY2025 EPS estimates for shares of Zentalis Pharmaceuticals in a note issued to investors on Tuesday, November 11th. Wedbush analyst R. Driscoll now forecasts that the company will earn ($1.68) per share for the year, up from their previous estimate of ($1.81). Wedbush has a “Neutral” rating and a $4.00 price objective on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q4 2025 earnings at ($0.31) EPS, FY2026 earnings at ($1.30) EPS, FY2027 earnings at ($1.04) EPS, FY2028 earnings at ($0.41) EPS and FY2029 earnings at $0.08 EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.12.

Other equities analysts have also issued reports about the stock. Morgan Stanley lowered their target price on shares of Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating for the company in a report on Wednesday. Wall Street Zen downgraded shares of Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a research note on Wednesday, October 8th. Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 price objective on shares of Zentalis Pharmaceuticals in a report on Tuesday. Finally, HC Wainwright upgraded Zentalis Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Zentalis Pharmaceuticals has an average rating of “Hold” and a consensus price target of $5.03.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ ZNTL opened at $1.32 on Thursday. Zentalis Pharmaceuticals has a 1 year low of $1.01 and a 1 year high of $4.16. The firm has a 50-day moving average of $1.53 and a 200 day moving average of $1.45. The stock has a market cap of $95.37 million, a P/E ratio of -0.64 and a beta of 1.87.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ZNTL. Cerity Partners LLC grew its position in shares of Zentalis Pharmaceuticals by 58.7% during the first quarter. Cerity Partners LLC now owns 20,501 shares of the company’s stock worth $33,000 after purchasing an additional 7,579 shares in the last quarter. SG Americas Securities LLC boosted its stake in Zentalis Pharmaceuticals by 35.3% in the 3rd quarter. SG Americas Securities LLC now owns 31,579 shares of the company’s stock worth $48,000 after purchasing an additional 8,236 shares during the period. State of Wyoming grew its holdings in Zentalis Pharmaceuticals by 30.1% during the 1st quarter. State of Wyoming now owns 45,176 shares of the company’s stock valued at $72,000 after buying an additional 10,460 shares in the last quarter. American Century Companies Inc. raised its position in shares of Zentalis Pharmaceuticals by 46.2% during the first quarter. American Century Companies Inc. now owns 46,900 shares of the company’s stock valued at $75,000 after buying an additional 14,816 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Zentalis Pharmaceuticals by 4.7% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 361,236 shares of the company’s stock valued at $574,000 after buying an additional 16,197 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.